Statistics for Correction to : Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1)
Total visits
| views | |
|---|---|
| Correction to : Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) (Radiation Oncology, (2021), 16, 1, (163), 10.1186/s13014-021-01888-1) | 0 |
Total visits per month
| views | |
|---|---|
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
File Visits
| views | |
|---|---|
| Hanna_et_al_correction_durval_Radiation_oncology_vor.pdf | 1 |